

Doc code: IDS

PTO/SB/08a (02-18)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 11/30/2020. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16789709
	Filing Date	2020-02-13
	First Named Inventor	Matthew During
	Art Unit	1629
	Examiner Name	R. T. Shiao
	Attorney Docket Number	2262-29-CON B CON II

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	10603308		2020-03-31	During	
	2	8461389		2013-06-11	Regan et al.	
	3	8618087	B2	2013-12-31	Shaw et al.	
	4	9339495		2016-05-17	During	
	5	9351968		2016-05-31	During	
	6	9399034		2016-07-26	During et al.	
	7	9446028		2016-09-20	During	
	8	9629853		2017-04-25	Jones et al.	

EFS Web 2.1.18

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16789709
	Filing Date		2020-02-13
	First Named Inventor	Matthew During	
	Art Unit	1629	
	Examiner Name	R. T. Shiao	
Attorney Docket Number		2262-29-CON B CON II	

	9	9682069		2017-06-20	During	
	10	9717716		2017-08-01	During et al.	
	11	10071083		2018-09-11	During	
	12	10363246		2019-07-30	During	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20070032553	A1	2007-02-08	McKernan et al.	
	2	20070112017	A1	2007-05-17	Barlow et al.	
	3	20070141161	A1	2007-06-21	Shaw et al.	
	4	20070259912	A1	2007-11-08	Cooper	
	5	20110034562	A1	2011-02-10	REGAN	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16789709
	Filing Date		2020-02-13
	First Named Inventor	Matthew During	
	Art Unit	1629	
	Examiner Name	R. T. Shiao	
	Attorney Docket Number	2262-29-CON B CON II	

6	20110046090	A1	2011-02-24	Barlow et al.	
7	20110172188	A1	2011-07-14	Mouthon et al.	
8	20120035207	A1	2012-02-09	McKernan et al.	
9	20130309306	A1	2013-11-21	Rogawski et al.	
10	20150313913	A1	2015-11-05	CATTERALL et al.	
11	20150352085	A1	2015-12-10	During	
12	20160038469	A1	2016-02-11	DURING	
13	20160228418	A1	2016-08-11	DURING	
14	20160228454	A1	2016-08-11	Zhang et al.	
15	20170014392	A1	2017-01-19	During	
16	20170014393	A1	2017-01-19	DURING	

EFS Web 2.1.18

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16789709
	Filing Date		2020-02-13
	First Named Inventor	Matthew During	
	Art Unit	1629	
	Examiner Name	R. T. Shiao	
Attorney Docket Number		2262-29-CON B CON II	

	17	20170065572	A1	2017-03-09	DURING	
	18	20170348232	A1	2017-12-07	DURING	
	19	20180042903	A1	2018-02-15	DURING	
	20	20180235942	A1	2018-08-23	DURING et al.	
	21	20180344708	A1	2018-12-06	During	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2006118897	WO	A1	2006-11-09	Merck & Co., Inc		
	2	2015189744	WO	A1	2015-12-17	Pfizer Ltd		
	3	2016127170	WO	A1	2016-08-11	Marinus Pharmaceuticals, Inc		

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16789709
	Filing Date	2020-02-13
	First Named Inventor	Matthew During
	Art Unit	1629
	Examiner Name	R. T. Shiao
	Attorney Docket Number	2262-29-CON B CON II

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Bahi-Buisson et al., Molecular Syndromology, 2011, 2: 137-152.	
	2	Archer et al., J. of Medical Genetics, 2006, 43(9):729-734.	
	3	Deuschl, "Treatment of patients with essential tremor," Lancet Neurol., (2011), vol. 10; pp. 148-161.	
	4	Teive, "Essential tremor: phenotypes," Parkinsonism and Related Disorders, 2012 (18S1); pp. S140-S142.	
	5	Gironell, "The GABA Hypothesis in Essential Tremor: Lights and Shadows," Tremor and Other Hyperkinetic Movements, (2014), vol. 4; pp. 1-9.	
	6	Ebert et al., "Treating Insomnia: Current and Investigational Pharmacological Approaches," Pharmacology & Therapeutics, (2006), vol. 112; pp. 612-629.	
	7	James K. Walsh, Ph.D., "Enhancement of Slow Wave Sleep: Implications for Insomnia," Journal of Clinical Sleep Medicine, (2009), Supplement to vol. 5, No. 2; pp. 827-832.	
	8	Glykys et al., "The Main Source of Ambient GABA Responsible for Tonic Inhibition in the Mouse Hippocampus," J Physiol, (2007), vol. 582, No. 3; pp. 1163-1178.	
	9	Iber et al., "The AASM Manual for the Scoring of Sleep and Associated Events," American Academy of Sleep Medicine (2007); pp. 3-59 (57 pages).	
	10	Jennum et al., "Sleep Disorders in Neurodegenerative Disorders and Stroke," European Handbook of Neurological Management, (2011), vol. 1, 2nd Edition, Chapter 39, Section 6—Sleep Disorders, (Ed. Gilhus et al.) Blackwell Publishing Ltd. 2011; pp.529-543.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16789709
	Filing Date	2020-02-13
	First Named Inventor	Matthew During
	Art Unit	1629
	Examiner Name	R. T. Shiao
	Attorney Docket Number	2262-29-CON B CON II

11	Jonas et al., "Neural Inhibition," Scholarpedia - http://www.scholarpedia.org/article/Neural_inhibition - (2014); 10 pages.
12	Egawa et al., "Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models." <i>Frontiers in Neural Circuits</i> , Oct. 24, 2013, vol. 7, Article 170; pp. 1-15.
13	El Idrissi et al., "Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse," <i>Neurosci Lett</i> (2005) vol. 377, No. 3; pp. 141-146.
14	Hagerman et al., "Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems", <i>Clinical Intervention in Aging</i> , 2008, vol. 3, No. 2; pp. 251-262.
15	Lennox-gastaut syndrome; Wikipedia article. dated Jul. 10, 2016; 11 pages.
16	Natural Patterns of Sleep - Healthy Sleep - (2007) http://healthysleep.med.harvard.edu/healthy/science/what/sleep-patterns-rem-nrem (2007); 3 pages.
17	Tropea et al., "Partial Reversal of Rett Syndrome-like Symptoms in MeCP2 Mutant Mice," <i>PNAS</i> , Feb. 10, 2009, vol. 106, No. 6; pp. 2029-2034.
18	Olmos-Serrano et al, "Defective GABAergic Neurotransmission and Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a Mouse Model of Fragile X Syndrome," <i>The Journal of Neuroscience</i> , Jul. 21, 2010, vol. 30, No. 29; pp. 9929-9938(25 pages).
19	Sarah DeWeerd, "Fragile X Mice Show Brain-Wave Abnormalities During Sleep," SFARI, Simons Foundation, Autism Research Initiative, Jan. 25, 2013; 2 pages.
20	Vardya et al., "Positive Modulation of .delta.-Subunit Containing GABAA Receptors in Mouse neurons," <i>Neuropharmacology</i> , (2012), vol. 63; pp. 469-479.
21	International Search Report and Written Opinion of the International Searching Authority, dated Sep. 27, 2016, corresponding to International Application No. PCT/US16/42238; 8 total pages.

EFS Web 2.1.18

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16789709
	Filing Date	2020-02-13
	First Named Inventor	Matthew During
	Art Unit	1629
	Examiner Name	R. T. Shiao
	Attorney Docket Number	2262-29-CON B CON II

22	International Search Report and Written Opinion, dated Oct. 4, 2016, corresponding to International Application No. PCT/US16/50702; 9 total pages.
23	International Search Report and Written Opinion of the International Searching Authority, dated Jul. 18, 2017, corresponding to International Application No. PCT/US17/34443; 5 total pages.
24	International Search Report and Written Opinion of the International Searching Authority, dated Aug. 26, 2015, corresponding to International Application No. PCT/US15/34018; 12 total pages.
25	Egawa et al., "Decreased Tonic Inhibition in Cerebellar Granule Cells Causes Motor Dysfunction in a Mouse Model of Angelman Syndrome," Neurodegenerative Disease, Science Translational Medicine, vol. 4, Issue 165 (163ra157), Dec. 5, 2012; pp. 1-10.
26	Brown et al., "Pharmacological Characterization of a Novel Cell Line Expressing Human .alpha.4.beta.3.delta. GABAA Receptors," British Journal of Pharmacology, (2002), vol. 136, No. 7; pp. 965-974.
27	International Search Report and Written Opinion of the International Searching Authority, dated Aug. 14, 2015, corresponding to International Application No. PCT/US2015/029155; 19 total pages.
28	Cao et al., "Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone," Human Molecular Genetics, 2012, vol. 21, No. 13, pp. 2923-2935.
29	Oakley et al., "Synergistic GABA-Enhancing Therapy against Seizures in a Mouse Model of Dravet Syndrome," The Journal of Pharmacology and Experimental Therapeutics, May 2013, vol. 345; pp. 215-224.
30	International Search Report and Written Opinion of the International Searching Authority, dated Oct. 31, 2017, corresponding to International Patent Application No. PCT/US17/46256; 10 total pages.
31	Loescher, W., "Development of Tolerance to the Anticonvulsant Effect of GABA-mimetic Drugs in Animal Models of Seizure States in Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs," Koella et al. (eds.), (1986); pp. 37-45.
32	Petersen et al., "THIP: A Single Blind Controlled Trial in Patients with Epilepsy," Acta Neurol. Scand. 67; pp. 114-117 (1983).

EFS Web 2.1.18

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16789709
	Filing Date		2020-02-13
	First Named Inventor	Matthew During	
	Art Unit	1629	
	Examiner Name	R. T. Shiao	
	Attorney Docket Number	2262-29-CON B CON II	

33	PCT Notice concerning Transmittal of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty), International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, dated Feb. 1, 2018, corresponding to International Application No. PCT/US2016/042238; 8 total pages.
34	Reagan-Shaw et al., "Dose translation from animal to human studies revisited", FASEB J, vol. 22, No. 3, Oct. 17, 2007; pp. 659-661.
35	International Search Report and Written Opinion of the International Searching Authority, dated Apr. 24, 2018, corresponding to International Application No. PCT/US18/16602; 15 total pages.
36	Bahi-Buisson et al., "The three stages of epilepsy in patients with CDKL5 mutations", Epilepsia, (2008), vol. 49, No. 6; pp. 1027-1037.
37	Tenney et al., "The Current State of Absence Epilepsy: Can We Have Your Attention?", Epilepsy Currents, Current Review in Clinical Science, vol. 13, No. 3 (May/Jun. 2013); pp. 135-140.
38	Bahi-Buisson et al., "CDKL5-Related Disorders: From Clinical Description to Molecular Genetics," Molecular Syndromology, (2011), vol. 2; pp. 137-152.
39	Monaghan et al., "Initial Human Experience with Ganaxolone, A Neuroactive Steroid with Antiepileptic Activity," Epilepsia, (1997), vol. 38, No. 9; pp. 1026-1031.
40	European Search Report dated Nov. 18, 2019, corresponding to European Application No. 19190461.4; 11 pages.
41	Charles A. Handforth, "GABA Receptor May Present Target for New ET Drug Therapy," Essential Tremor, Jun. 4, 2013; 1 page.
42	Charles A. Handforth, "A Delta GABA Receptor as a Target for Essential Tremor Therapy," National Institutes of Health, Jun. 10, 2015; 4 pages.
If you wish to add additional non-patent literature document citation information please click the Add button Add	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16789709
	Filing Date	2020-02-13
	First Named Inventor	Matthew During
	Art Unit	1629
	Examiner Name	R. T. Shiao
	Attorney Docket Number	2262-29-CON B CON II

EXAMINER SIGNATURE			
Examiner Signature	/REI TSANG SHIAO/	Date Considered	06/08/2020
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16789709
	Filing Date	2020-02-13
	First Named Inventor	Matthew During
	Art Unit	1629
	Examiner Name	R. T. Shiao
	Attorney Docket Number	2262-29-CON B CON II

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jeffrey S. Steen, Reg. #32063/	Date (YYYY-MM-DD)	2020-05-13
Name/Print	Jeffrey S. Steen	Registration Number	32,063

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.